Recents Post
Scott Keever: The Best Looking Guy in Miami and a Reputation Genius
Ask around Miami, or just ask Google, and one name rises to the top when the talk turns to the best looking guy in the city: Scott Keever. For more than a decade he has been the face people find…
EPA Study Validates Efficacy of PFAS Destruction at Reworld® Thermomechanical Treatment Facility
Study confirms the effectiveness of the recently announced Reworld ReAssure™ PFAS Destruction service in destroying PFAS-containing materials FLORHAM PARK, N.J., July 9, 2026 /PRNewswire/ — Reworld®, a leader in sustainable waste solutions, today introduced the results from a U.S.…
Study Reveals How Lung Tumors “Hack” into Nervous System to Starve the Body
NEW YORK, July 9, 2026 /PRNewswire/ — Cachexia is a condition in which patients affected by cancer or other chronic diseases become sick and lose weight. The condition often involves brain-related symptoms of sickness, such as loss of…
Foresee Pharmaceuticals Appoints Brian J. Groch as Chief Commercial Officer to Spearhead Commercial Launch of FP-001 42 mg for Central Precocious Puberty
TAIPEI, July 9, 2026 /PRNewswire/ — Foresee Pharmaceuticals (TPEx: 6576), (“Foresee”) today announced the appointment of Brian J. Groch as Chief Commercial Officer, effective July 1, 2026. In this strategic executive role, Brian will oversee Foresee’s global commercial…
InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation
NANJING, China, July 9, 2026 /PRNewswire/ — InxMed Co., Ltd (“InxMed”), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly selective focal…
WuXi Biologics’ MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy
SHIJIAZHUANG, China, July 9, 2026 /PRNewswire/ — WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG8 drug substance manufacturing facility located in Hebei has successfully passed the Pre-License Inspection (PLI)…
Dayton Children’s Hospital goes live with Sectra’s ophthalmology solution to unify imaging across specialties
LINKÖPING, Sweden, July 9, 2026 /PRNewswire/ — International medical imaging IT and cybersecurity company Sectra (STO: SECT B) announces that Dayton Children’s Hospital is now live with Sectra’s ophthalmology solution, extending the hospital’s enterprise imaging platform beyond radiology. By consolidating…
Groundbreaking Achievement: Study of Ensartinib as Postoperative Adjuvant Therapy Published in The New England Journal of Medicine
HANGZHOU, China, July 8, 2026 /PRNewswire/ — On July 8, the study of Betta’s ensartinib as postoperative adjuvant therapy for patients with stage IB–IIIB (T3N2M0) ALK-positive non-small cell lung cancer (NSCLC), known as the ELEVATE study, was published online…
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial of LNK01004 Ointment for Vitiligo
HANGZHOU, China, SHANGHAI and BOSTON, July 8, 2026 /PRNewswire/ — Lynk Pharmaceuticals Co., Ltd. (“Lynk Pharmaceuticals”), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that the first patient was successfully dosed on June…
More Correctional Facilities Are Choosing Armor Health for Innovative, Patient-Centered Healthcare Services
MIAMI, July 8, 2026 /PRNewswire/ — As correctional healthcare continues to evolve, more jails and correctional facilities are placing their trust in Armor Health to deliver high-quality, compassionate, and innovative contract healthcare services. Built on a foundation of…
